Debut, the biotech beauty leader, has secured an investment of $20 million to accelerate the expansion of its proprietary, AI-based ingredient discovery platform. This platform will help advance skin longevity innovation and scale its formulation business in the U.S. and Asia.

Joshua Britton, PhD, Founder and CEO of Debut, said,

“Debut is laser-focused on staying at the forefront of skincare innovation and bringing cutting-edge biotech to every beauty brand with the highest-performing and most differentiated ingredients. This funding will enhance our ability to screen upward of 50 billion ingredients to explore the 99.999 percent of unknown molecules that can optimize skin health and make skin longevity a reality.”

The funding will propel the discovery of next-generation ingredients that target the 14 hallmarks of aging and empower Debut’s global beauty partners to innovate with peak-performing biotech ingredients and formulations married to novel claims.

It will also enable beauty brands at all stages of growth to outsource their formulation innovation in record time, at scale, and without the heavy upfront R&D expense associated with biotech.

Debut’s funding raise comes at a time marked by increased investor caution. The company is poised to enter the Asian market which is driven by advanced formulations and high-performance skincare.

Debut’s expansion into Asia will begin in Singapore, where the company will be partnering with leading brands to create custom ingredients and formulations for longevity skincare.

The most recent fundraising round was supported by Fine Structure Ventures, EDBI, Wealthberry, BOLD (the venture fund of L’Oréal), GS Futures, Sandbox Industries and Material Impact, among others.

Read Next

L’Oréal Signs Long-Term Partnership with Biotech Firm, Debut

Biotech Company Debut Launches AI-Powered Ingredient Discovery Platform